Glenn Goddard - 01 Jan 2024 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role
EVP, Chief Financial Officer
Signature
James Basta, attorney-in-fact
Issuer symbol
NTLA
Transactions as of
01 Jan 2024
Net transactions value
$0
Form type
4
Filing time
03 Jan 2024, 17:28:42 UTC
Previous filing
03 Mar 2023
Next filing
05 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTLA Common Stock Options Exercise +3,062 +7.1% 45,950 01 Jan 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NTLA Restricted Stock Unit Options Exercise $0 -3,062 -50% $0.000000 3,064 01 Jan 2024 Common Stock 3,062 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2 On March 3, 2021, the reporting person was granted 12,250 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter.